FDA approves IND application for peanut allergen vaccine. Phase I study in peanut allergy patients to begin May 2022

Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut

  • Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022
  • Topline data from first-in-human trial expected in H1 2023
  • Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of action of the vaccine candidate

Full details: